The assessment of the therapeutic effectiveness of IRS-19 in allergic children with recurrent or chronic respiratory infections.
The subject of the clinical-laboratory examinations was a group of 36 children aged 1 4/12 - 17 years with recurrent upper (94%) and lower (63%) airway infections, whose condition did not improve after antibiotic therapy, elimination diet and anti-histaminic treatment. In 83% of the examined patients respiratory tract symptoms co-existed with skin (61%), gastrointestinal tract (44%) and OUN (16%) diseases. 75% of examined children, with humoral and/or cellular response disorders, were given an IRS-19 vaccine, which resulted in the regression of the respiratory tract symptoms in 78% of patients. Due to side-effects in the form of high temperature, the treatment was terminated in 14% of children. The obtained therapeutic effects and convenience of administration of the vaccine, justify IRS-19 treatment in children with recurrent lower and upper airway infections, after complex immunological examination.
Maciorkowska
E
E
Third Department of Pediatrics, Medical Academy of Białystok.
Kaczmarski
M
M
Cudowska
B
B
Stasiak-Barmuta
A
A
Nowowiejska
B
B
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D001419:Bacteria; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications; D007223:Infant; D008297:Male; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; C079233:IRS 19